

BioArctic - BMS deal a promising start for BBB-platform, Leqembi ramp up slower than expected

Redeye return with a research update following BioArctic's Q1 report and capital markets day. We reiterate our positive long-term view but account for Eisai's latest Leqembi forecast and simulations as well as the weaker USD/SEK, leading to a slighly lower valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BioArctic - BMS deal a promising start for BBB-platform, Legembi ramp up slower than expected